Medical Condition News

RSS

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013

Military deployment increases risk of maternal depression in female service members

About 16,000 women on active duty in the U.S. military give birth each year. Most return to service after 6 weeks and can be deployed after 4 months. The potential for an increased risk of depression among new mothers who deploy and are exposed to combat experience is presented in a study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

13 Feb 2013

Less than 1 in 4 young people with ASD receive transition services

Health care transition (HCT) services help young people with special health care needs such as asthma or diabetes move from pediatric to adult health care. However, youths with autism spectrum disorder (ASD) have less access to these services, which are designed to prevent gaps in care and insurance coverage.

13 Feb 2013

Platelet-rich plasma holds great promise in treating knee OA

A study by researchers from Hospital for Special Surgery has shown that platelet-rich plasma (PRP) holds great promise for treating patients with knee osteoarthritis.

13 Feb 2013

Scopolamine may also be possible treatment for anxiety disorders

However, scopolamine is re-emerging as an antidepressant, with recent studies showing that scopolamine can rapidly improve mood in depressed patients. In addition, in a new study published in Biological Psychiatry this month by Dr. Moriel Zelikowsky and colleagues at the University of California, Los Angeles, it may also be a possible treatment for anxiety disorders.

13 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

Excess weight gain, obesity during pregnancy may increase risk of macrosomia

Epidemiologists at Boston University School of Public Health (BUSPH) have found that pre-pregnancy obesity and excess weight gain during pregnancy in African-American women are associated with an increased risk of giving birth to an abnormally large baby.

13 Feb 2013

Ziziphora may be effective in treatment of gastric cancer

A recent publication in the journal Food and Agricultural Immunology investigating the effects of aloe vera, ginger, saffron and ziziphora extracts as herbal remedies for gastric cancer suggests that the latter may be effective in the treatment of the fourth most common form of the disease.

13 Feb 2013

Early detection, treatment needed to reduce risk of death and CVD in older Cushing's disease patients

Even after successful treatment, patients with Cushing's disease who were older when diagnosed or had prolonged exposure to excess cortisol face a greater risk of dying or developing cardiovascular disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

13 Feb 2013

More opioids being prescribed for pain relief in Germany

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse with health insurance from a large statutory provider is published in the latest issue of Deutsches Ärzteblatt International.

13 Feb 2013

New medication could help patients with renal tumours triggered by tuberous sclerosis

In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).

13 Feb 2013

Study finds abnormal production of C9RANT in patients with ALS, frontotemporal dementia

Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders — amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia.

13 Feb 2013

Researchers call for increased regulation of food, drink companies for improvement of global public health

"Multinational food, drink and alcohol companies are using strategies similar to those employed by the tobacco industry to undermine public health policies, health experts said on Tuesday," Reuters reports.

13 Feb 2013

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

March is National Autoimmune Disease Awareness Month 2013. To mark the annual event, the American Autoimmune Related Diseases Association Inc. (AARDA) is encouraging the national and local media around the country to report stories on autoimmune diseases (AD) and autoimmunity as a category of disease.

13 Feb 2013

Dance-related injuries on the rise among children and adolescents

Dance is a beautiful form of expression, but it could be physically taxing and strenuous on the human body, particularly for children and adolescents. A new study by researchers at the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital examined dance-related injuries among children and adolescents 3 to 19 years of age from 1991 to 2007.

13 Feb 2013

Abnormal TDP-43 protein causes death of astrocytes in motor neurone disease

A discovery using stem cells from a patient with motor neurone disease could help research into treatments for the condition. The study used a patient's skin cells to create motor neurons - nerve cells that control muscle activity - and the cells that support them called astrocytes.

13 Feb 2013

University of Utah geneticists engineer mice that develop clear cell sarcoma

Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form.

13 Feb 2013

RNAi effective in treating cancer patients

The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.

13 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.

13 Feb 2013

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013